Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
Status:
Completed
Trial end date:
2021-01-09
Target enrollment:
Participant gender:
Summary
Tofacitinib suppresses pro-inflammatory signaling that may be important pathogenetically to
progression to more severe lung disease and acute respiratory distress syndrome (ARDS) in
patients with COVID-19. The purpose of the study is to assess the safety and efficacy of
tofacitinib plus standard pharmacologic and supportive measures in treating hospitalized
participants with COVID-19 pneumonia.